Ultra-pure agonists of guanylate cyclase C, method of making and using same
Kunwar Shailubhai, Audubon, PA (US); Stephen Comiskey, Doylestown, PA (US); Rong Feng, Langhorne, PA (US); Juncai Bai, North Augusta, SC (US); Ruoping Zhang, North Augusta, SC (US); Jun Jia, Shanghai (CN); Junfeng Zhou, Shanghai (CN); Qiao Zhao, Shanghai (CN); and Guoqing Zhang, Shanghai (CN)
Assigned to Bausch Health Ireland Limited, Dublin (IE)
Filed by Bausch Health Ireland Limited, Dublin (IE)
Filed on Nov. 16, 2023, as Appl. No. 18/511,852.
Application 18/511,852 is a continuation of application No. 18/193,144, filed on Mar. 30, 2023, granted, now 11,834,521.
Application 18/193,144 is a continuation of application No. 17/397,796, filed on Aug. 9, 2021, abandoned.
Application 17/397,796 is a continuation of application No. 17/207,215, filed on Mar. 19, 2021, abandoned.
Application 17/207,215 is a continuation of application No. 16/921,450, filed on Jul. 6, 2020, granted, now 11,142,549, issued on Oct. 12, 2021.
Application 16/921,450 is a continuation of application No. 16/000,251, filed on Jun. 5, 2018, granted, now 10,745,441, issued on Aug. 18, 2020.
Application 16/000,251 is a continuation of application No. 14/896,019, granted, now 10,011,637, issued on Jul. 3, 2018, previously published as PCT/US2014/041143, filed on Jun. 5, 2014.
Claims priority of provisional application 61/831,402, filed on Jun. 5, 2013.
Prior Publication US 2024/0287137 A1, Aug. 29, 2024
1. An oral formulation comprising a purified peptide comprising a Guanylate Cyclase-C(GCC) agonist of amino acid sequence of SEQ ID NO: 1, wherein the purified peptide has less than 0.25% alpha-Asp-9-plecanatide relative to the weight of the purified peptide.